Key Takeaways & Executive Findings
- •• GC002, a novel gold(I) phosphine complex, demonstrates superior cytotoxicity against hepatocellular carcinoma (HCC) cells compared to sorafenib and auranofin. • GC002 induces irreversible necroptosis in HCC cells through elevated reactive oxygen species (ROS) accumulation. • Mechanistically, GC002 directly binds to and inhibits thioredoxin reductase (TrxR), disrupting redox homeostasis in cancer cells. • In vivo xenograft studies confirm GC002's potent antitumor activity with minimal side effects, highlighting its therapeutic potential for HCC.
Abstract
Hepatocellular carcinoma (HCC), the predominant type of liver cancer, is an aggressive malignancy with limited therapeutic options. In this study, we assess a collection of newly designed gold(I) phosphine complexes. Remarkably, the compound GC002 exhibits the greatest toxicity to HCC cells and outperforms established medications, such as sorafenib and auranofin, in terms of antitumor efficacy. GC002 triggers irreversible necroptosis in HCC cells by increasing the intracellular accumulation of reactive oxygen species (ROS). Mechanistically, GC002 significantly suppresses the activity of thioredoxin reductase (TrxR), which plays a crucial role in regulating redox homeostasis and is often overexpressed in HCC by binding directly to the enzyme. Our in vivo xenograft study confirms that GC002 possesses remarkable antitumor activity against HCC without severe side effects. These findings not only highlight the novel mechanism of controlling necroptosis via TrxR and ROS but also identify GC002 as a promising candidate for the further development of antitumor agents targeting HCC.
1. Introduction
Hepatocellular carcinoma (HCC), the primary malignant tumor of the liver, has been recognized as the fifth most diagnosed and the second most lethal cancer worldwide [1]. Currently, the most effective treatments for HCC are surgical resection and liver transplantation [2]. However, patients are often diagnosed with HCC in an advanced state and miss the opportunity for curative resection. Although immune checkpoint inhibitors and molecularly targeted drugs, such as sorafenib and lenvatinib, have been used in the clinical management of HCC in recent years, HCC remains as one of the cancers with the poorest prognosis due to challenges such as drug resistance and frequent tumor metastasis and recurrence [3,4]. Therefore, identifying more effective HCC treatments remains a crucial and emerging field of research.
Redox control systems are essential for cellular homeostasis. They manage the tightly regulated balance between the production and elimination of reactive oxygen species (ROS) and reactive nitrogen species (RNS) [5]. At the core of this system is the thioredoxin (Trx) system, which consists of NADPH, Trx, and TrxR [6,7]. TrxR, a member of the pyridine nucleotide disulfide oxidoreductase family, is known for its ability to reduce disulfide bonds (-S-S-) to dithiol (-SH) groups, a process that is crucial for oxidative stress defense [8]. By reducing Trx, TrxR facilitates the transfer of electrons to peroxiredoxin (Prx), subsequently eliminating intracellular harmful ROS. Consequently, the thioredoxin system plays a pivotal role in maintaining a balanced state of oxidation and reduction within cells.
Loading authentic research manuscript (Pages 1–5)...
Yuan Wang, Haokun Yuan, Ruiqin Fang, Ran Zhang, Wei-jia Wang (2026). Unveiling the cytotoxicity of a new gold(I) complex towards hepatocellular carcinoma by inhibiting TrxR activity. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2024155
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the main finding of this study?
The study identifies a new gold(I) complex, GC002, which shows potent cytotoxicity against hepatocellular carcinoma (HCC) cells by inhibiting thioredoxin reductase (TrxR) activity, leading to increased reactive oxygen species (ROS) and necroptosis.
How does GC002 compare to existing HCC treatments?
GC002 outperforms established medications such as sorafenib and auranofin in terms of antitumor efficacy against HCC cells, as demonstrated in the study.
What is the mechanism of action of GC002?
GC002 directly binds to and inhibits thioredoxin reductase (TrxR), disrupting redox homeostasis and causing accumulation of reactive oxygen species (ROS), which triggers irreversible necroptosis in HCC cells.
What are the potential clinical implications of this research?
The findings suggest that GC002 could be a promising candidate for developing new antitumor agents targeting HCC, with in vivo studies showing remarkable antitumor activity and minimal side effects.
What is the significance of targeting TrxR in cancer therapy?
TrxR is often overexpressed in tumors, including HCC, and plays a crucial role in maintaining redox homeostasis. Inhibiting TrxR can disrupt the antioxidant defense of cancer cells, leading to oxidative stress and cell death, making it a promising therapeutic strategy.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.